Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MLTX 
MoonLake Immunotherapeutics (MLTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: MLTX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.61
1 Year Target Price $14.61
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.66% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 945.81M USD | Price to earnings Ratio - | 1Y Target Price 14.61 |
Price to earnings Ratio - | 1Y Target Price 14.61 | ||
Volume (30-day avg) 16 | Beta 1.24 | 52 Weeks Range 5.95 - 62.75 | Updated Date 12/4/2025 |
52 Weeks Range 5.95 - 62.75 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.8788 | Actual -1.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.72% | Return on Equity (TTM) -54.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 582256460 | Price to Sales(TTM) - |
Enterprise Value 582256460 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -41.53 | Shares Outstanding 70847401 | Shares Floating 35662441 |
Shares Outstanding 70847401 | Shares Floating 35662441 | ||
Percent Insiders 9.82 | Percent Institutions 60.72 |
Upturn AI SWOT
MoonLake Immunotherapeutics
Company Overview
History and Background
MoonLake Immunotherapeutics was founded in 2021. It is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory skin and joint diseases. Their lead product candidate is Sonelokimab.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of Sonelokimab for the treatment of hidradenitis suppurativa (HS) and other inflammatory diseases.
- Clinical Trials: Conducting Phase 2b and Phase 3 clinical trials to evaluate the safety and efficacy of Sonelokimab.
Leadership and Structure
Dr. Ardian Lilly is the CEO. The company operates with a focused leadership team overseeing clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Sonelokimab: Sonelokimab is a Nanobody targeting IL-17A/F heterodimer. It is currently in clinical trials for hidradenitis suppurativa (HS) and other inflammatory diseases. There is currently no revenue or market share yet as the drug is not approved. Competitors include Humira (AbbVie), Cosentyx (Novartis), and Taltz (Eli Lilly).
Market Dynamics
Industry Overview
The market for inflammatory disease treatments is large and growing, driven by the increasing prevalence of conditions like HS and psoriasis. There's a high unmet need for more effective and targeted therapies.
Positioning
MoonLake is positioned as a company developing a potentially best-in-class IL-17A/F inhibitor with the potential to address unmet needs in inflammatory diseases.
Total Addressable Market (TAM)
The TAM for HS treatment alone is estimated to be several billion dollars. MoonLake aims to capture a significant portion of this market with Sonelokimab, if approved.
Upturn SWOT Analysis
Strengths
- Novel IL-17A/F Nanobody
- Promising Clinical Trial Results
- Strong Intellectual Property
- Experienced Management Team
Weaknesses
- Limited Financial Resources Compared to Larger Pharma
- Dependence on a Single Product Candidate
- Clinical Trial Risks
- No approved products or revenue
Opportunities
- Successful Completion of Clinical Trials
- Regulatory Approval for Sonelokimab
- Expansion to Other Inflammatory Diseases
- Partnerships with Larger Pharmaceutical Companies
Threats
- Competition from Existing Therapies
- Clinical Trial Failures
- Regulatory Hurdles
- Patent Challenges
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- LLY
Competitive Landscape
MoonLake aims to compete with existing therapies by offering a potentially more effective and convenient treatment option. Key competitive advantages would include superior efficacy, improved safety profile, or less frequent dosing.
Growth Trajectory and Initiatives
Historical Growth: MoonLake has grown rapidly since its founding, primarily through investment in clinical development.
Future Projections: Future growth is highly dependent on the successful completion of Phase 3 clinical trials and regulatory approval of Sonelokimab. Analyst estimates vary widely.
Recent Initiatives: Initiated Phase 3 trials for Sonelokimab in HS. Secured financing to support clinical development.
Summary
MoonLake Immunotherapeutics is a clinical-stage biotech company with a promising lead drug candidate, Sonelokimab. While they have no revenue, they are focusing on clinical trials. Success hinges on the outcomes of these trials and regulatory approval. They must maintain a strong cash position and navigate the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change. Investing in biotechnology companies involves significant risks, including clinical trial failures and regulatory setbacks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MoonLake Immunotherapeutics
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-20 | Co-Founder, CEO & Director Dr. Jorge Santos da Silva Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.moonlaketx.com |
Full time employees 100 | Website https://www.moonlaketx.com | ||
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.